Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors

29 Apr 2025 14:19 CEST

Oslo, Norway, April 29, 2025 – The Ordinary General Meeting of Lytix Biopharma
AS ("Lytix" or the "Company") was held on April 29, 2025. All proposed
resolutions on the agenda were approved.

As part of the General Meeting, a new Board of Directors was elected in line
with the recommendation from the Nomination and Compensation Committee to
further reinforce the company. The newly appointed board members bring broad and
complementary experience across business development, oncology, fundraising,
clinical development, regulatory strategy, and financial oversight. These
additions will strengthen the Lytix team and enhance Lytix’s chances of quickly
bringing new therapeutic options to patients with cancer and create value for
the shareholders.

The new board consists of the following members:

• Eric Falcand (Chair): More than 37 years of international leadership and
management experience in the pharmaceutical industry; he has led over 50
licensing and partnership agreements globally, including transformative M&A,
many of which focused on oncology and immuno-oncology innovations.

• Julie Dehaene-Puype: Pharmaceutical executive with 25 years of international
experience in General Management, Commercial Operations, Sales & Marketing, New
Products Development and Regulatory Affairs.

• Claus Andersson: More than 25+ years of venture experience and experience from
more than 20 international boards

• Marie-Louise Fjällskog: More than 25 years of experience in clinical oncology,
translational research, and drug development.

• Brynjar Forbergskog: CEO of Saturn Invest AS and responsible for evolving
Torghatten ASA into one of the largest transportation groups in the Nordic
region

• Kjetil Hestdal: Senior Life Science Executive and previously the Chief
Executive Officer of Photocure ASA - a commercial-stage company focused on
bladder cancer

Eric Falcand, Julie Dehaene-Puype and Claus Andersson will complement the
continuing members of the board and collectively provide a strong foundation for
the company’s future direction.

“I am very honored to join Lytix as Chair of the Board and to work alongside
such a diverse and experienced team,” said Eric Falcand, newly elected Chair.
“Lytix has a promising technology platform and a clear ambition to advance their
immuno-oncology drug candidates to the benefit of patients. Together with the
board and the management, I look forward to contributing to the company’s
strategic growth and long-term value creation.”

“We are very pleased to welcome our new chairman and the new board members,”
said Øystein Rekdal, CEO of Lytix Biopharma. “Their collective experience across
scientific, clinical, and commercial areas will strengthen our capabilities to
accelerate development, expand partnerships, and strengthen our position within
the immuno-oncology space.”

The Company would also like to extend its sincere thanks to the outgoing board
members — Marie Roskrow (Chair), Jayson Rieger, and Evelina Vågesjö — for their
service and valuable contributions. Their efforts have been appreciated and have
helped position Lytix for the next phase of development.

Minutes of the meeting are attached hereto.

The minutes and all documents relevant for the annual general meeting are
available on the Company's website: www.lytixbiopharma.com.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

More information:
Access the news on Oslo Bors NewsWeb site

644732_Lytix - AGM minutes 2025 - Final - Signert.pdf